Latest News

Dishman Carbogen Amcis Ltd Commissions India’s Largest PWP Distribution Network at Bavla

News

Dishman Carbogen Amcis Ltd Commissions India’s Largest PWP Distribution Network at Bavla

Phase-I of the GMP-compliant purified water (PW) system is now fully operational at the company's Bavla CDMO site, supplying four production units to 100% microbiological and chemical compliance. 

Gujarat, INDIA (September 2026) – Ahmedabad-based Dishman Carbogen Amcis Ltd, a global contract development and manufacturing organization (CDMO), has successfully completed Phase-I of its new Purified Water (PW) generation and distribution system at its Bavla manufacturing site in Gujarat, India. The system, engineered and supplied by BWT Switzerland — the same technology partner that serves Carbogen Amcis Switzerland — is now in continuous operation, supplying Units 1, 2, 6 and 6B. It has been independently recognized by CN-BWT as the largest purified water installation in terms of distribution network and POUs commissioned at any pharmaceutical manufacturing site in India to date. 

Why Purified Water Systems Matter for CDMO and Pharmaceutical Manufacturing 

In pharmaceutical manufacturing, purified water is a critical raw material and utility, used across API synthesis, formulation, equipment cleaning, and sanitization. For a CDMO running multiple production units under one quality umbrella, the reliability, capacity, and regulatory compliance of the purified water system directly affect manufacturing uptime, batch release timelines, and client audit outcomes. The new system at Bavla was engineered to meet these demands at scale, supporting current API and formulation output while building in headroom for future site expansion. 

Engineering Scale and Automation for High-Volume CDMO Operations 

Designed for a generation capacity of up to 144 kilolitres per day, the purified water plant is connected via a piping network exceeding 8 kilometres in length. This extensive network is sized not only for present requirements but also to accommodate future site expansion without the need for structural rework. 

The entire operation is governed by a centralized control system with full interlock integration, enabling automated, closed-loop management across the generation and distribution loops. This sophisticated automation minimizes manual intervention points, significantly reducing the risk of contamination—a critical factor for any GMP-compliant pharmaceutical manufacturing infrastructure. 

Multi-Stage Purification Train Ensures Pharma-Grade Water Quality 

Water quality is maintained through a multi-stage treatment train, each stage targeting a specific class of contaminant: 

  • Bewazon — pre-treatment microbial control 
  • Osmotron — conductivity control via reverse osmosis 
  • Septron — electrodeionization (EDI) combined with ultrafiltration 
  • Steritron — final microbial control 
  • Online TOC monitoring — continuous verification of total organic carbon 

This staged architecture allows each critical quality parameter — bioburden, conductivity, endotoxin-related organics, and total organic carbon — to be controlled and monitored independently, rather than relying on a single point of control. Since commissioning, Phase-I has demonstrated 100% compliance with all microbiological and chemical acceptance criteria, delivering consistent pharma-grade water quality across every connected production unit. 

GMP, 21 CFR and GAMP-5 Compliance for Regulatory-Ready CDMO Manufacturing 

The purified water system is managed under a compliance framework aligned to 21 CFR Part-11, GAMP-5, ASME, and DIN standards, supporting both regulatory audit readiness and long-term data integrity. For a CDMO serving global pharmaceutical clients, this level of documented, standards-based compliance is a prerequisite for client qualification audits and regulatory inspections across multiple markets. 

Sustainable Water Treatment Supports ESG Goals in Pharmaceutical Manufacturing 

A key differentiator of this system is its sanitization method. Sanitization across the network is performed using ozone rather than the traditional hot-water sanitization cycles commonly found in ordinary setups. This innovative approach offers significant sustainability and operational advantages: 

  • Reduced Energy Consumption: Ozone sanitization requires less energy compared to heating large volumes of water. 
  • Shorter Cycle Times: The process is faster, improving overall system efficiency. 
  • Zero Water Waste: Critically, the water used in ozone sanitization remains usable after the cycle. In stark contrast, traditional hot-water sanitization requires the water to be drained and discarded, placing a significant load on the Effluent Treatment Plant (ETP). This new approach eliminates water loss, reduces ETP burden, and contributes directly to the site's broader ESG and sustainable manufacturing objectives. 

A Milestone for CDMO Capacity and Quality at the Bavla Site 

Taken together, the capacity, redundant purification architecture, and centralized automation make this system a world-class utility platform for the Bavla site — one built to support current manufacturing demand while remaining ready for future growth. The successful completion of Phase-I reflects sustained cross-functional coordination, and the Engineering department's contribution to delivering a system of this scale and complexity has been central to its success. 

Frequently Asked Questions 

What is a purified water (PW) system in pharmaceutical manufacturing? 

A purified water system generates and distributes water that meets pharmacopoeial quality standards, such as USP and Ph. Eur., for use in non-parenteral pharmaceutical manufacturing, including formulation, equipment cleaning, and rinsing. 

Why is GMP-compliant purified water important for CDMOs? 

CDMOs manufacture on behalf of multiple pharmaceutical clients, so consistent, GMP-compliant water quality directly affects batch compliance, client audits, and regulatory approvals across every program run through the facility. 

What standards does the Bavla purified water plant comply with? 

The system is managed under a compliance framework aligned to 21 CFR Part-11, GAMP-5, ASME, and DIN standards, and has demonstrated 100% compliance with all microbiological and chemical acceptance criteria since commissioning. 

How does ozone sanitization support sustainable pharmaceutical manufacturing? 

Ozone-based sanitization reduces energy use and cycle time compared with heat- or chemical-based methods, and eliminates the water loss typically associated with hot-water sanitisation, directly supporting site-level ESG targets. 

Read more …Dishman Carbogen Amcis Ltd Commissions India’s Largest PWP Distribution Network at Bavla

  • Hits: 773

Dishman signs MoU with IIT Gandhinagar

News

DCAL Signs MoU with IIT Gandhinagar to Drive Innovation in Pharmaceuticals, Healthcare and AI

Ahmedabad, Gujarat, INDIA – [11 June, 2026] – Dishman Carbogen Amcis Ltd (DCAL) has signed a Memorandum of Understanding (MoU) with IIT Gandhinagar under the institute’s Healthcare & MedTech Research Cluster (HMRC), launched on 11 June 2026.

DCAL has entered into a Memorandum of Understanding (MoU) with IIT Gandhinagar under the institute’s Healthcare & MedTech Research Cluster (HMRC), launched on 11 June 2026. This strategic partnership marks a significant step towards strengthening industry–academia collaboration and fostering innovation in the pharmaceutical and healthcare sectors.

The collaboration establishes a framework for joint research, technology development, and knowledge exchange across key areas, including pharmaceutical process chemistry, formulation science, analytical methodologies, artificial intelligence (AI), digital technologies, and software solutions for healthcare and pharmaceutical applications. By combining academic excellence with industry expertise, the partnership aims to accelerate the translation of research into scalable, real-world solutions that enhance product quality, operational efficiency, and regulatory compliance.

As part of the agreement, DCAL and IIT Gandhinagar will work together on the development of AI-driven platforms, data analytics solutions, automation tools, and digital transformation initiatives to address emerging challenges in pharmaceutical manufacturing and healthcare technologies. The collaboration will also provide opportunities for joint research projects, skill development programmes, faculty and student engagement, internships, and collaborative problem-solving. In addition, DCAL will gain access to IIT Gandhinagar’s Central Instrumentation Facility and multidisciplinary academic expertise, further strengthening its innovation capabilities.

Aligned with the Government of India’s Viksit Bharat vision, this partnership reinforces the role of industry–academia collaboration in advancing indigenous research, promoting AI-enabled healthcare solutions, and driving sustainable growth within India’s pharmaceutical and MedTech ecosystem.

Read more …Dishman signs MoU with IIT Gandhinagar

  • Hits: 2631

A successful inspection by MFDS at Naroda site further strengthens DISHMAN CARBOGEN AMCIS LIMITED global quality compliance

News

A successful inspection by MFDS at Naroda site further strengthens DISHMAN CARBOGEN AMCIS LIMITED global quality compliance

Gujarat, INDIA (June 2026) – Ahmedabad-based Dishman Carbogen Amcis Ltd (DCAL), a pharmaceutical API manufacturing and drug development company, successfully completed an inspection by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, at its Naroda manufacturing facility.

DCAL is pleased to announce the successful completion of an inspection by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, at its Naroda manufacturing site.

The successful inspection reflects the continued strength of the site's quality management systems, regulatory compliance framework, and operations. It reinforces the company's commitment to maintaining the highest standards of quality, patient safety, and Good Manufacturing Practices (GMP).

"The successful completion of the MFDS inspection underscores our unwavering commitment to quality, compliance, and operational excellence. This achievement also reflects the dedication and expertise of our teams, whose relentless focus enables us to consistently meet the best standards expected by global regulatory authorities and customers. This milestone also reinforces our global footprint and enhances our ability to accelerate growth across the APAC region, underpinned by trust and long-term partnerships.”

— [Paolo Armanino], Chief Operating Officer, DCAL

As a trusted global partner to the pharmaceutical industry, DCAL remains focused on continuously enhancing its capabilities while delivering reliable and compliant solution worldwide aimed at patient safety and customer success.

 

 

 

Read more …A successful inspection by MFDS at Naroda site further strengthens DISHMAN CARBOGEN AMCIS LIMITED...

  • Hits: 1858

Dishman Carbogen Amcis Ltd announces successful USFDA inspection of its Naroda facility

News

Dishman Carbogen Amcis Ltd announces successful USFDA inspection of its Naroda facility
 

AHMEDABAD, India (June 13, 2025) - Dishman Carbogen Amcis Ltd’ Naroda manufacturing facility went through an inspection by the USFDA between 9th to 12th June, 2025, which was concluded without any observations, confirming that no concerns were identified.

Paolo Armanino, COO of Dishman Carbogen Amcis Ltd, spoke about the company's achievement regarding the recent USFDA inspection: 

"Once again, the successful completion of the USFDA inspection, without observations, of our Naroda manufacturing facility reaffirms our organisation’s commitment to consistently maintaining the highest quality standards over time.  

 I want to extend my heartfelt congratulations to all team members for their dedication and hard work. I am also extremely proud of all our subject matter experts across India who supported the pre-inspection activities. 

 The successful inspection at Naroda, along with last year's approvals from PMDA Japan, EDQM/AIFA, and the USFDA for our Bavla site, underscores Dishman Carbogen Amcis Ltd’ track record of delivering high-quality manufacturing services. 

 I would like to take this opportunity to sincerely appreciate the company’s promoters, who have been instrumental and played a crucial role in supporting the quality strategy. Their efforts have ensured that all Dishman group pharma facilities are established and maintained according to the highest international standards.”  

****

Dishman Carbogen Amcis Ltd (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, in China and in India.

CARBOGEN AMCIS (www.carbogen-amcis.com) is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS is a wholly owned subsidiary of Dishman Carbogen Amcis Ltd, Ahmedabad, India.

OTHER NEWS

Company Profile

CONTACT US TODAY OR DOWNLOAD
OUR COMPANY PROFILE BROCHURE
FOR FURTHER INFORMATION

SUBSCRIBE TO OUR MAILING LIST FOR THE LATEST NEWS UPDATES

Read more …Dishman Carbogen Amcis Ltd announces successful USFDA inspection of its Naroda facility

  • Hits: 31912

Dishman Carbogen Amcis Ltd receives 'Choose France - Best Indian Investment in France' award from the Indo French Chamber of Commerce and Industry (IFFCI)

News

Dishman Carbogen Amcis Ltd receives 'Choose France - Best Indian Investment in France' award from the Indo French Chamber of Commerce and Industry (IFFCI)

NEW DELHI, India, (April 18, 2024) – Dishman Carbogen Amcis Ltd received the Choose France-Best Indian Investment in France award by the Indo French Chamber of Commerce & Industry in partnership with Business France India, at the sixth flagship event of the Indo-French Business Awards (IFBA) and Grand Prix VIE, in New Delhi. His Excellency Mr. Thierry Mathou, Ambassador of France presented the award which recognises Dishman’s investment in a new state-of-the-art facility in Saint Beauzire, France, and the increase in Human Capital over the last few years.

 

Giving a detailed overview of the company's facility in Saint Beauzire and future business plans, Mr. Harshil Dalal, Group CFO - Dishman Group, stated:

“We thank the Indo French Chamber of Commerce and Industry for this wonderful recognition of our efforts to make France our destination of choice to do business."

 

Dishman Carbogen Amcis Ltd stands as a beacon of innovation and progress in the healthcare industry, transcending borders with our multi-site transcontinental presence. With 11 manufacturing sites and 6 sales offices spread across 6 countries, and subsidiaries in key regions like Switzerland, France, Netherlands, UK, and China, we're poised to deliver comprehensive healthcare solutions like never before.

Our journey in France epitomizes our commitment to growth and excellence. In 2012, we acquired a small but promising company, igniting a transformative journey in the realm of Sterile Investigational Medicinal Products (IMPS). Specializing in complex compounds, this facility became a nucleus for innovation, crafting aseptic drug products for preclinical and clinical batches in various forms.

Fast forward to 2023, a milestone year as we inaugurated our state-of-the-art facility in Saint Beauzire. With a Euro 58 million investment, this cutting-edge 9500 m2 establishment symbolizes our dedication to pushing boundaries. Operational since October 2023, it hosts over 100 skilled professionals, a testament to our commitment to job creation and skill development.

Our growth trajectory is not just about numbers; it's about impact. From a modest headcount of 34 in 2018-19, we've surged to 120 by March 2024, with sights set on reaching 200 by March 2028. This expansion isn't just about revenue; it's about societal contribution. From Euro 5 million annually to a projected Euro 40 million, our growth isn't just corporate—it's communal.

Beyond financial gains, our France site embodies potential. It's a gateway to new markets, a hub for R&D, and a catalyst for groundbreaking therapies like anti-cancer drugs. As we expand, so does our organizational backbone, with 70 new positions created, heralding a future brimming with opportunities.

Reflecting on our journey, we've come a long way from our humble beginnings. Yet, amidst our growth, the most profound transformation is the confidence we hold in the future—a future shaped by relentless innovation, unwavering dedication, and boundless potential."

Read more …Dishman Carbogen Amcis Ltd receives 'Choose France - Best Indian Investment in France' award from...

  • Hits: 14956